Holen Sie sich die Stockscreener-App
547.67
2.36%
-13.26
Handel nachbörslich:
544.70
-2.97
-0.54%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Daily Progress: Regeneron Pharmaceuticals, Inc (REGN) Gain 0.43, Closing at 560.93 - DWinneX
Regeneron Pharmaceuticals, Inc. (REGN): Among the Cheap ESG Stocks to Buy According to Hedge Funds - Yahoo Finance
Capitolis Liquid Global Markets LLC Acquires 49,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Cutter Capital Management LP's Largest Position - MarketBeat
Baird Financial Group Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Ameriprise Financial Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Axa S.A. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Investment Analysts’ Recent Ratings Updates for Regeneron Pharmaceuticals (REGN) - Defense World
Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition - insights.citeline.com
Myopic macular degeneration Market: Epidemiology, Therapies, - openPR.com
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
Aplastic anemia Market: Epidemiology, Therapies, Companies, - openPR.com
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
Regeneron Pharmaceuticals (REGN): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Caisse DE Depot ET Placement DU Quebec Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Benzinga
Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM - Rare Cancer News
Westbourne Investments Inc. Takes $356,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Bellevue Group AG - MarketBeat
Diabetic Retinopathy Market Set to Witness Significant Growth - openPR.com
Banque Transatlantique SA Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
UBS Group Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
AQR Capital Management LLC Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron, Amgen Open Drug 'Bundling' Trial In Del. - Law360
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
Schonfeld Strategic Advisors LLC Buys 18,496 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Comerica Bank Sells 1,364 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Retinal Vein Occlusion Market Size, Trends & Growth Forecast - openPR.com
Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Voleon Capital Management LP Acquires Shares of 671 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Earnings Miss - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Misses Estimates By $0.61 EPS - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
PDT Partners LLC Buys 3,057 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Public Employees Retirement Association of Colorado Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
California State Teachers Retirement System Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Northern Trust Corp Has $751.39 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria - MSN
Cantor Fitzgerald Issues Positive Outlook for REGN Earnings - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to “Hold” at StockNews.com - Defense World
UBS Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $633.00 - Defense World
Pinebridge Investments L.P. Has $2.83 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nebula Research & Development LLC - MarketBeat
Regeneron (REGN) Declares Quarterly Dividend of $0.88/Share - GuruFocus
Retinal Vein Occlusion Market Projected To Witness Massive - openPR.com
Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition - insights.citeline.com
FY2025 EPS Estimates for REGN Raised by Cantor Fitzgerald - Defense World
Regeneron announces significant expansion of US manufacturing capacity - The Manufacturer
Aquatic Capital Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Boothbay Fund Management LLC Has $8.82 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences - simplywall.st
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’ - MSN
8.64%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):